BrightGene Bio-Medical Technology Co

BrightGene Bio-Medical Technology Co Net Debt / EBITDA

The Net Debt to EBITDA of BrightGene Bio-Medical Technology Co (688166.SS) as of Nov 22, 2026 is 12.60. In the previous year, Net Debt to EBITDA was 5.39 — a change of 133.64% (higher).

Net Debt / EBITDA

12.60

YoY

133.64%

Last updated:

Net Debt to EBITDA of BrightGene Bio-Medical Technology Co is 2025 12.60 . Net Debt to EBITDA of BrightGene Bio-Medical Technology Co was 2024 5.39 . It decreases by 133.64% higher compared to the previous year.

The BrightGene Bio-Medical Technology Co Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2020
0.34 CNY
Jan 1, 2021
2.08 CNY
Jan 1, 2022
5.26 CNY
Jan 1, 2023
5.59 CNY
Jan 1, 2024
5.39 CNY
Jan 1, 2025
12.60 CNY
The BrightGene Bio-Medical Technology Co Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
12.60+133.64%
5.39-3.54%
5.59+6.34%
5.26+152.89%
2.08+506.83%
0.34—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BrightGene Bio-Medical Technology Co Stock analysis

What does BrightGene Bio-Medical Technology Co do? BrightGene Bio-Medical Technology Co., Ltd. generates revenue by researching, developing, and manufacturing biopharmaceuticals, medicines, and special generic active pharmaceutical ingredients and finished dosage forms. The company's product portfolio centers on antifungal, antiviral, and immunosuppressive APIs, alongside other APIs and preparations. Its generic drug offerings specifically include entecavir, caspofungin, micafungin, posaconazole, everolimus, and fondaparinux sodium. The firm sells these products to customers in both domestic and overseas markets. By leveraging its capabilities in producing essential active pharmaceutical ingredients and finished dosage forms, the company serves the broader pharmaceutical sector through its established manufacturing and research operations. BrightGene Bio-Medical Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BrightGene Bio-Medical Technology Co stock

Net Debt to EBITDA of BrightGene Bio-Medical Technology Co is 12.60 in 2025.

Net Debt to EBITDA of BrightGene Bio-Medical Technology Co changed from 5.39 to 12.60, representing a 133.64% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA BrightGene Bio-Medical Technology Co since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's BrightGene Bio-Medical Technology Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — BrightGene Bio-Medical Technology Co

All Key Metrics — BrightGene Bio-Medical Technology Co